Qiagen (NYSE:QGEN) Given New $55.00 Price Target at JPMorgan Chase & Co.

Qiagen (NYSE:QGEN) had its price target upped by equities research analysts at JPMorgan Chase & Co. from $50.00 to $55.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 20.77% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 11th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Barclays set a $40.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Citigroup reissued a “neutral” rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Finally, Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Qiagen currently has an average rating of “Hold” and a consensus price target of $43.93.

Qiagen Stock Performance

NYSE QGEN traded up $0.10 during trading hours on Wednesday, reaching $45.54. The stock had a trading volume of 1,632,435 shares, compared to its average volume of 2,464,141. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The stock has a fifty day moving average of $43.59 and a 200 day moving average of $40.20. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The stock has a market cap of $9.38 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 4.51 and a beta of 0.61.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. Qiagen’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts predict that Qiagen will post 2.43 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors have recently added to or reduced their stakes in QGEN. GAMMA Investing LLC acquired a new position in shares of Qiagen during the 3rd quarter valued at about $345,000. State Street Corp increased its position in Qiagen by 4.5% during the second quarter. State Street Corp now owns 2,183,206 shares of the company’s stock worth $85,363,000 after purchasing an additional 93,575 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Qiagen during the second quarter worth about $252,000. WINTON GROUP Ltd acquired a new stake in Qiagen during the second quarter worth about $1,423,000. Finally, Engineers Gate Manager LP increased its position in Qiagen by 107.7% during the second quarter. Engineers Gate Manager LP now owns 74,567 shares of the company’s stock worth $2,916,000 after purchasing an additional 38,658 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.